(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known ...
The U.S. Food and Drug Administration today approved Basaglar (insulin glargineinjection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...
A new form of insulin just hit American markets. It's called Basaglar, and it is 15% less than the list price of Lantus and Toujeo, two long-acting insulins made by Sanofi Aventis, 21% less than the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback